ConductScience.org, home
PLA2R1: phospholipase A2 receptor 1
API referenceFor AI assistants

Gene · 22925

Papers2,349

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 2,349

Download this page as JSON
TitleJournalYearPMIDFound bySource
LAMA5 pathogenic variant uncovers a novel autoantigen in membranous nephropathy.Genes Dis202742763546PubTator, text miningPubMed
Diagnostic pitfall: NSAID-induced membranous nephropathy with PLA2R positivity, IgG1-predominant deposits, C1q positivity, and concurrent acute interstitial nephritis-A case report.Clin Chim Acta202742503368PubTator, text miningPubMed
Rituximab Outcomes and Predictors of Treatment Failure in Primary Membranous Nephropathy: A Retrospective Cohort Study.J Clin Med202642795840PubTator, text miningPubMed
The role of serum BAFF, CFB, MCP-1 and anti-PLA2R antibodies in the efficacy evaluation of patients with membranous nephropathy.J Med Biochem202642781234PubTator, text miningPubMed
Risk prediction of PLA2R-Ab-negative membranous nephropathy: an interpretable multicenter machine learning model.Front Immunol202642746065PubTator, text miningPubMed
Anti-PLA2R autoantibodies induce complement activation via IgG subclass-dependent epitope pairings in membranous nephropathy.J Clin Invest202642709482PubTator, text miningPubMed
From immune dysregulation to renal injury: mechanistic insights and translational opportunities in immune-mediated nephropathies.Front Cell Dev Biol202642707564PubTator, text miningPubMed
Histopathological predictors of renal outcomes in idiopathic membranous nephropathy with a focus on global sclerotic glomeruli ratio.Sci Rep202642706286PubTator, text miningPubMed
An unusual presentation of membranous nephropathy with primary and secondary features: a case report.BMC Nephrol202642687155PubTator, text miningPubMed
Comparison of efficacy and safety among four therapeutic regimens in primary membranous nephropathy with high anti-PLA2R antibody titers: a single-center retrospective cohort study.BMC Nephrol202642687143PubTator, text miningPubMed
Efficacy and safety of telitacicept for rituximab-refractory membranous nephropathy.Int Urol Nephrol202642686924PubTator, text miningPubMed
Obinutuzumab Compared to Cyclosporine with Steroids for the Treatment of Primary Membranous Nephropathy: A Propensity Score-Matched Analysis.Kidney360202642684841PubTator, text miningPubMed
Emerging Immune Cell Biomarkers in Primary Membranous Nephropathy: Immune Cell Profiling During Anti-CD20 B Cell-Targeted Therapy.Int J Mol Sci202642653236PubTator, text miningPubMed
MPO-ANCA-associated glomerulonephritis with immune complex deposition and membranous features in a patient with Sjögren's syndrome: a case report.CEN Case Rep202642645684PubTator, text miningPubMed
A comparative study on the efficacy of rituximab combined with tacrolimus and methylprednisolone in the treatment of patients with moderate-high risk idiopathic membranous nephropathy.Am J Transl Res202642630345PubTator, text miningPubMed
Clinical phenotype predicts anti-PLA2R serology in nephrotic range proteinuria.Nefrologia (Engl Ed)202642618194PubTator, text miningPubMed
Anti-PLA2R antibody levels are associated with thromboembolism risk in individuals with membranous nephropathy and hypoalbuminemia.J Nephrol202642598914PubTator, text miningPubMed
Diagnostic performance and inter-observer reproducibility of glomerular PLA2R immunohistochemistry in primary membranous nephropathy: a multi-laboratory blinded observer study.BMC Nephrol202642581347PubTator, text miningPubMed
Predicting membranous nephropathy remission: a nomogram based on early dynamic biomarkers.Front Med (Lausanne)202642549141PubTator, text miningPubMed
Association between anti-PLA2R antibody status and clinical remission in primary membranous nephropathy: a systematic review and meta-analysis.Int Urol Nephrol202642507287PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/22925/papers

API referenceFor AI assistants